Patented technology for the production of full-length, correctly folded and functional proteins
Identify all autoantigens and antigens that make up the Autoproteome*
(*) Totality of all possible autoantigens and neoantigens representing a given disease and its sub-types
lmmuSAFE™ is a novel, lab-based biochip test for COVID-19 that enables highly quantitative determination of both the level and target location of SARS-CoV-2 antibodies in an individual. The test answers 4 fundamental questions:
1. Confirming with high accuracy whether an individual has been infected with the virus that causes COVID-19.
2. Determining whether the level and target location of the antibodies in an individual are likely to offer protectivity.
3. Confirming that an individual has generated a sufficiently strong immune response to the vaccine to confer protection.
4. Retesting to confirm the status of ongoing protection and evaluating whether a booster vaccine is required.
lmmuSAFE™ utilises Sengenics’ patented KREX™ protein folding technology ensuring that viral antigens are correctly folded, preserving all conformational and linear antibody binding sites. Multiple domains of SARS-CoV-2 Nucleocapsid and Spike proteins including both full-length and numerous truncated versions are used in the tests.
The biochip enables the determination of the target epitopes, titres and immunoglobulin class/sub-class (IgG, IgA, IgM; IgG1-4) of antibodies produced across all stages of COVID-19 infection, from initial exposure, disease development, post-recovery or post-vaccination. lmmuSAFE™ can also enable quantitative assessment of patient response in vaccination trials, including differentiation of whether observed antibody responses are due directly to the vaccine or to prior SARS-CoV-2 exposure.
ImmuSAFE™ can be utilised for vaccine clinical trials or sero-prevalence research studies.
The target epitope of antibodies produced following infection exhibit a significant level of diversity across a population. ImmuSAFE™ provides a more accurate determination of sero-prevalence by targeting multiple domains of SARS-CoV-2 proteins.
Some individuals produce antibodies that target locations which are neutralising (protective), whereas others produce non-neutralising antibodies. ImmuSAFE™ can be used to identify individuals who have high titres of potentially neutralising antibodies against SARS-CoV-2.
Investigate SARS-CoV-2 specific immunoreactivity in patients and healthy individuals for vaccine development, safety and efficacy determination in clinical trials.
As shown below, data from the ImmuSAFE™ test enables 3 major conclusions to be inferred:
Relative IgG titres in convalescent COVID-19 patient and healthy sera against different domains of SARS-CoV-2 nucleocapsid [For illustration purposes only].
The ImmuSAFE™ product range also includes other biochip-based tests that incorporate additional viral antigens. Content can be customised based on individualised requirements for vaccine clinical trials or sero-prevalence research studies.
| Code | Product Description |
|---|---|
| 39508H | ImmuSAFE™ COVID+ Protein Microarray contains multiple SARS-CoV-2 specific domains (Nucleocapsid and Spike proteins) including full-length and numerous truncated versions and INF, TNF, ANA etc. Key applications are vaccine clinical trials and sero-prevalence research studies. |
High-throughput autoantibody profiling against 1600+ proteins
Quantification of autoantibodies to 200+ clinically relevant CT antigens
Simultaneous screening of 100+
wild-type and mutant p53
Multi-antigen, multi-domain
COVID-19 antibody test
